Eagle Asset Management Inc Akebia Therapeutics, Inc. Transaction History

Eagle Asset Management Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 08, 2018	SELL	$7.44 - $10.65 $21 Million - $30.1 Million	-2,824,403 Closed	0 $0
Q2 2018 Aug 07, 2018	BUY	$9.15 - $11.34 $904,312 - $1.12 Million	98,832 Added 3.63%	2,824,403 $28.2 Million
Q1 2018 May 09, 2018	BUY	$9.53 - $15.68 $89,620 - $147,454	9,404 Added 0.35%	2,725,571 $26 Million
Q4 2017 Feb 09, 2018	SELL	$14.24 - $19.59 $4.67 Million - $6.42 Million	-327,700 Reduced 10.77%	2,716,167 $40.3 Million
Q3 2017 Nov 09, 2017	BUY	$13.06 - $19.67 $39.8 Million - $59.9 Million	3,043,867	3,043,867 $59.6 Million

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $353M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Eagle Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Eagle Asset Management Inc with notifications on news.